Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura

Blood

Volumn 127, Issue 24, 2016, Pages 3092-3094

  Page, Evaren E ^a,b   Kremer Hovinga, Johanna A ^c   Terrell, Deirdra R ^a   Vesely, Sara K ^a   George, James N ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; IMMUNOLOGIC FACTOR;

ADULT; AGED; BACTEREMIA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; LETTER; MALE; PLASMA EXCHANGE; PRIMARY IMMUNE THROMBOCYTOPENIA; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; RISK REDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; MIDDLE AGED; PROCEDURES; RECURRENT DISEASE; SECONDARY PREVENTION; YOUNG ADULT;

ADAMTS13 PROTEIN; ADRENAL CORTEX HORMONES; ADULT; AGED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; RITUXIMAB; SECONDARY PREVENTION; YOUNG ADULT;

EID: 84976337802     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-03-703827     Document Type: Letter

References (8)

1. Lim W, Vesely SK, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015;125(10):1526-1531.
2. Froissart A, Veyradier A, Hié M, Benhamou Y, Coppo P; French Reference Center for Thrombotic Microangiopathies. Rituximab in autoimmune thrombotic thrombocytopenic purpura: a success story. Eur J Intern Med. 2015;26(9):659-665.
3. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746-1753.
4. Froissart A, Buffet M, Veyradier A, et al; French Thrombotic Microangiopathies Reference Center; Experience of the French Thrombotic Microangiopathies Reference Center. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Crit Care Med. 2012;40(1):104-111.
5. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500-1511, quiz 1662.
6. Pintilie M. Competing Risks: A Practical Perspective. New York, NY: John Wiley and Sons; 2006.
7. George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher. 2006;21(1):49-56.
8. Peyvandi F, Scully M, Kremer Hovinga JA, et al; TITAN Investigators. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511-522.